Navigation Links
For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
Date:5/18/2009

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the TNF-alpha inhibitors, in particular, and constrain the biologics market," said Decision Resources Analyst Joanna Kim, M.Ed. "The potential of this oral Jak-3 inhibitor was demonstrated by its impressive efficacy in a recent Phase II clinical study for rheumatoid arthritis."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes
2. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
3. Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
4. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
5. An Aid to Tailoring Prostate Cancer Treatment
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
8. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
9. Can New Surgery Revolutionize Diabetes Treatment?
10. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
11. New Cancer Treatment Achieves First Mesothelioma Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has issued an important reminder to employers to ... Employers with workers exposed to high temperatures should establish a complete heat ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: